Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles

Brain Research Bulletin

Volumn 74, Issue 1-3, 2007, Pages 119-129

  Ioja, Eniko ^a   Tourwé, Dirk ^b   Kertész, István ^a   Tóth, Géza ^a   Borsodi, Anna ^a   Benyhe, Sándor ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Antagonists; CHO cells; G protein activation; Opioid receptors; Partial agonism; Radioligand binding; Rat brain; Tritium labeling

Indexed keywords

2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLIC ACID BETA METHYLPHENYLALANINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MU OPIATE RECEPTOR; OPIATE ANTAGONIST; OPIATE PEPTIDE; OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BRAIN MEMBRANE; CHINESE HAMSTER; CIS TRANS ISOMERISM; CONTROLLED STUDY; DIASTEREOISOMER; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ANALGESICS, OPIOID; ANIMALS; BRAIN; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); NARCOTIC ANTAGONISTS; OLIGOPEPTIDES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, OPIOID; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES; TRITIUM; TYROSINE;

EID: 34547543568     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2007.05.010     Document Type: Article

References (60)

1. Abdelhamid E.E., Sultana M., Portoghese P.S., and Takemori A.E. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther. 258 (1991) 299-303
2. Amodeo P., Balboni G., Crescenzi O., Guerrini R., Picone D., Salvadori S., Tancredi T., and Temussi P.A. Conformational analysis of potent and very selective delta opioid dipeptide antagonists. FEBS Lett. 377 (1995) 363-367
3. Arakawa K., Akami T., Okamoto M., Nakajima H., Mitsuo M., Nakai I., Oka T., Nagase H., and Matsumoto S. Immunosuppressive effect of delta-opioid receptor antagonist on xenogeneic mixed lymphocyte reaction. Transplant. Proc. 24 (1992) 696-697
4. 5)-enkephalinamide. FEBS Lett. 76 (1977) 91-92
5. 7, an endogenous neuropeptide, binds to multiple opioid and nonopioid sites in rat brain. J. Neurosci. Res. 48 (1997) 249-258
6. 5-enkephalin to brain regions and spinal cord and pharmacological responses to morphine in the rat. Gen. Pharmacol. 24 (1993) 1351-1357
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
8. Bryant S.D., Jinsmaa Y., Salvadori S., Okada Y., and Lazarus L.H. Dmt and opioid peptides: a potent alliance. Biopolymers 71 (2003) 86-102
9. Clark M.J., Emmerson P.J., Mansour A., Akil H., Woods J.H., Portoghese P.S., Remmers A.E., and Medzihradsky F. Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor. J. Pharm. Exp. Ther. 283 (1997) 501-510
10. Cowan, Zhu X.Z., Mosberg H.I., Omnaas J.R., and Porreca F. Direct dependence studies in rats with agents selective for different types of opioid receptor. J. Pharm. Exp. Ther. 246 (1988) 950-955
11. Erspamer V., Melchiorri P., Falconieri-Erspamer G., Negri L., Corsi R., Severini C., Barra D., Simmaco M., and Kreil G. Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 5188-5192
12. Froehlich J.C., Badia-Elder N.E., Zink R.W., McCullough D.E., and Portoghese P.S. Contribution of the opioid system to alcohol aversion and alcohol drinking behavior. J. Pharm. Exp. Ther. 287 (1998) 284-292
13. Fundytus M.E., Schiller P.W., Shapiro M., Weltrowska G., and Coderre T.J. Attenuation of morphine tolerance and dependence with the highly selective delta-opioid receptor antagonist TIPP[Ψ]. Eur. J. Pharmacol. 286 (1995) 105-108
14. Galligan J.J., Mosberg H.I., Hurst R., Hruby V.J., and Burks T.F. Cerebral delta opioid receptors mediate analgesia but not the intestinal motility effects of intracerebroventricularly administered opioids. J. Pharm. Exp. Ther. 229 (1984) 641-648
15. Gardell L.R., Hubbell C.L., and Reid L.D. Naltrexone persistently reduces rats' intake of a palatable alcoholic beverage. Alcohol. Clin. Exp. Res. 20 (1996) 584-588
16. 35S]GTPgammaS binding assay: approaches and applications in pharmacology. Life Sci. 74 (2003) 489-508
17. House R.V., Thomas P.T., Kozak J.T., and Bhargava H.N. Suppression of immune function by non-peptidic delta opioid receptor antagonists. Neurosci. Lett. 198 (1995) 119-122
18. Hruby V.J., al Obeidi F., and Kazmierski W. Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations. Biochem. J. 268 (1990) 249-262
19. Hruby V.J., Li G., Haskell-Luevano C., and Shenderovich M. Design of peptides, proteins, and peptidomimetics in chi space. Biopolymers 43 (1997) 219-266
20. Ioja E., Tóth G., Benyhe S., Tourwé D., Peter A., Tömböly C., and Borsodi A. Opioid receptor binding characteristics and structure-activity studies of novel tetrapeptides in the TIPP (Tyr-Tic-Phe-Phe) series. Neurosignals 14 (2005) 317-328
21. Ko M.C., Lee H., Harrison C., Clark M.J., Song H.F., Naughton N.N., Woods J.H., and Traynor J.R. Studies of mu-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys. J. Pharm. Exp. Ther. 306 (2003) 179-186
22. Krishnan-Sarin S., Portoghese P.S., Li T.K., and Froehlich J.C. The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol. Biochem. Behav. 52 (1995) 153-159
23. Lazarus L.H., Bryant S.D., Cooper P.S., and Salvadori S. What peptides these deltorphins be. Prog. Neurobiol. 57 (1999) 377-420
24. 2 on kappa receptor selectivity and potency. J. Med. Chem. 39 (1996) 2456-2460
25. Mansour, Lewis M.E., Khachaturian H., Akil H., and Watson S.J. Pharmacological and anatomical evidence of selective mu, delta, and kappa opioid receptor binding in rat brain. Brain Res. 399 (1986) 69-79
26. Martin N.A., Terruso M.T., and Prather P.L. Agonist Activity of the delta-antagonists TIPP and TIPPΨ in cellular models expressing endogenous or transfected delta-opioid receptors. J. Pharm. Exp. Ther. 298 (2001) 240-248
27. Martin N.A., Ruckle M.B., VanHoof S.L., and Prather P.L. Agonist, antagonist, and inverse agonist characteristics of TIPP (H-Tyr-Tic-Phe-Phe-OH), a selective delta-opioid receptor ligand. J. Pharm. Exp. Ther. 301 (2002) 661-671
28. Menkens K., Bilsky E.J., Wild K.D., Portoghese P.S., Reid L.D., and Porreca F. Cocaine place preference is blocked by the delta-opioid receptor antagonist, naltrindole. Eur. J. Pharmacol. 219 (1992) 345-346
29. Motulsky H.J. Analysing Data with GraphPad Prism (1999), Graph Pad Software Inc., San Diego. CA. www.graphpad.com
30. 5,6deltorphin II. Neuropeptides 26 (1994) 261-265
31. 3H]TIPP. Life Sci 53 (1993) 57-62
32. Nevin S.T., Tóth G., Weltrowska G., Schiller P.W., and Borsodi A. Synthesis and binding characteristics of tritiated TIPP[Ψ], a highly specific and stable delta opioid antagonist. Life Sci. 56 (1995) 225-230
33. Park H.S., Lee H.Y., Kim Y.H., Park J.K., Zvartau E.E., and Lee H. A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability. Bioorg. Med. Chem. Lett. 16 (2006) 3609-3613
34. Pfeiffer, Brantl V., Herz A., and Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. Science 233 (1986) 774-776
35. Portoghese P.S., Lipkowski A.W., and Takemori A.E. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci. 40 (1987) 1287-1292
36. Portoghese P.S., Sultana M., and Takemori A.E. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur. J. Pharmacol. 146 (1988) 185-186
37. Reid L.D., Hubbell C.L., Glaccum M.B., Bilsky E.J., Portoghese P.S., and Porreca F. Naltrindole, an opioid delta receptor antagonist, blocks cocaine-induced facilitation of responding for rewarding brain stimulation. Life Sci. 52 (1993) L67-L71
38. Reid L.D., Glick S.D., Menkens K.A., French E.D., Bilsky E.J., and Porreca F. Cocaine self-administration and naltrindole, a delta-selective opioid antagonist. Neuroreport 6 (1995) 1409-1412
39. Remmers A.E., Clark M.J., Mansour A., Akil H., Woods J.H., and Medzihradsky F. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. J. Pharm. Exp. Ther. 288 (1999) 827-833
40. Rothman R.B., Gorelick D.A., Heishman S.J., Eichmiller P.R., Hill B.H., Norbeck J., and Liberto J.G. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J. Subst. Abuse Treat. 18 (2000) 277-281
41. Saitoh, Yoshikawa Y., Onodera K., and Kamei J. Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats. Psychopharmacology (Berlin) 182 (2005) 327-334
42. Salvadori S., Guerrini R., Balboni G., Bianchi C., Bryant S.D., Cooper P.S., and Lazarus L.H. Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism. J. Med. Chem. 42 (1999) 5010-5019
43. Schiller P.W., Fundytus M.E., Merovitz L., Weltrowska G., Nguyen T.M., Lemieux C., Chung N.N., and Coderre T.J. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J. Med. Chem. 42 (1999) 3520-3526
44. Schiller P.W., Nguyen T.M., Weltrowska G., Wilkes B.C., Marsden B.J., Lemieux C., and Chung N.N. Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 11871-11875
45. Schiller P.W., Weltrowska G., Berezowska I., Nguyen T.M., Wilkes B.C., Lemieux C., and Chung N.N. The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. Biopolymers 51 (1999) 411-425
46. Schiller P.W., Weltrowska G., Nguyen T.M., Wilkes B.C., Chung N.N., and Lemieux C. TIPP[Ψ]: a highly potent and stable pseudopeptide delta opioid receptor antagonist with extraordinary delta selectivity. J. Med. Chem. 36 (1993) 3182-3187
47. Schiller P.W., Weltrowska G., Schmidt R., Berezowska I., Nguyen T.M., Lemieux C., Chung N.N., Carpenter K.A., and Wilkes B.C. Subtleties of structure-agonist versus antagonist relationships of opioid peptides and peptidomimetics. J. Rec. Sign. Transduct. Res. 19 (1999) 573-588
48. Spetea M., Monory K., Tömböly C., Tóth G., Tzavara E., Benyhe S., Hanoune J., and Borsodi A. In vitro binding and signaling profile of the novel mu opioid receptor agonist endomorphin 2 in rat brain membranes. Biochem. Biophys. Res. Commun. 250 (1998) 720-725
49. Spetea M., Harris H.E., Berzetei-Gurske I.P., Klareskog L., and Schmidhammer H. Binding, pharmacological and immunological profiles of the delta-selective opioid receptor antagonist HS 378. Life Sci. 69 (2001) 1775-1782
50. 35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. J. Pharm. Exp. Ther. 283 (1997) 1276-1284
51. Tóth G., Lovas S., and Ötvös F. Tritium labeling of neuropeptides. Methods Mol. Biol. 73 (1997) 219-230
52. Tourwé D., Mannekens E., Diem T.N., Verheyden P., Jaspers H., Tóth G., Peter A., Kertesz I., Torok G., Chung N.N., and Schiller P.W. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile. J. Med. Chem. 41 (1998) 5167-5176
53. Tourwé D., Verschueren K., Frycia A., Davis P., Porreca F., Hruby V.J., Tóth G., Jaspers H., Verheyden P., and Van Binst G. Conformational restriction of Tyr and Phe side chains in opioid peptides: information about preferred and bioactive side-chain topology. Biopolymers 38 (1996) 1-12
54. Tourwé D., Van den Eynde I., Piron J., Carlens G., Tóth G., Ceusters M., Jurzak M., Heylen L., and Meert T. Combined 2′6′-dimethyltyrosine and ß-mehylphenylalanine substitutions in TIPP provide potent δ-opioid ligands. In: Benedetti E., and Pedone C. (Eds). Peptides 2002, Proceedings of the 27th European Peptide Symposium. Sorrento, Italy/Edizioni Ziino, Napoly, Italy (2002) 310-311
55. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47 (1995) 848-854
56. Vavrek R.J., Cui R.L., and Stewart J.M. Selectivity of minimum structure enkephalins. Life Sci. 31 (1982) 2249-2252
57. 5]enkephalin. Life Sci. 45 (1989) 1001-1008
58. Walsh S.L., Strain E.C., Abreu M.E., and Bigelow G.E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berlin) 157 (2001) 151-162
59. Weiland G.A., and Molinoff P.B. Quantitative analysis of drug-receptor interactions. I. Determination of kinetic and equilibrium properties. Life Sci. 29 (1981) 313-330
60. Zadina J.E., Hackler L., Ge L.J., and Kastin A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386 (1997) 499-502